This page is part of the PACIO Personal Functioning and Engagement Implementation Guide (v2.0.0-ballot: STU 2 Ballot 1) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 1.0.0. For a full list of available versions, see the Directory of published versions
Generated Narrative: AllergyIntolerance PFEIG-AllergyACE
clinicalStatus: Active
verificationStatus: Confirmed
category: Medication
criticality: High Risk
code: Substance with angiotensin-converting enzyme inhibitor mechanism of action (substance)
patient: Betsy Smith-Johnson Female, DoB Unknown ( http://example.org/identifiers/patient#10A3D58WH1600)
asserter: Betsy Smith-Johnson Female, DoB Unknown ( http://example.org/identifiers/patient#10A3D58WH1600)
lastOccurrence: 2011-10
Substance | Manifestation |
captopril 12.5 MG Oral Tablet | Hyperkalemia caused by angiotensin-converting enzyme inhibitor (disorder) |